Stacey Jennifer Evans Increases Stake in Context Therapeutics
Insider Stacey Jennifer Evans purchased 45,000 shares of Context Therapeutics on June 24.
Key Points
- Stacey Jennifer Evans bought 45,000 shares of Context Therapeutics on June 24, 2026, with the stock trading near $0.56.
- Context Therapeutics, a biotech firm, has a market cap of about $51.5 million and a 52-week high of $3.62.
- Analysts maintain a strong buy on CNTX, with a consensus target price of $5.38 from eight opinions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Stacey Jennifer Evans purchased 45,000 shares of Context Therapeutics Inc. (NasdaqCM: CNTX) on June 24, 2026. This insider transaction comes as the stock traded near $0.56 on that day.
Insider Buying and Selling at Context Therapeutics Inc.
Several insiders, including Stacey Jennifer Evans, bought 45,000 shares each of Context Therapeutics on June 24, 2026. The transactions were not part of any pre-planned trading arrangements. Other insiders like Karen Smith and Andy Pasternak also participated in similar purchases.
Other Institutional Activity in Context Therapeutics
Soleus Capital Management, L.P. opened a new position in Context Therapeutics with 6,963,141 shares valued at approximately $18.2 million. Similarly, Octagon Capital Advisors LP initiated a stake with 5,250,000 shares worth about $13.8 million. Meanwhile, Blue Owl Capital Holdings LP reduced its holdings by 2,343,891 shares, leaving it with 5,089,015 shares valued at around $13.3 million.
Context Therapeutics Inc. Stock Up 51.2%
On Saturday, shares of Context Therapeutics traded near $0.56. The biopharmaceutical company has a market cap of approximately $51.5 million. It is currently not profitable, so it has no meaningful P/E ratio. The stock's 52-week range is between $0.55 and $3.62, with a 50-day moving average of $2.01 and a 200-day moving average of $1.78. The company maintains a healthy current ratio of 8.96.
$CNTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 16, 2026, Maxim Group maintained its buy rating on Context Therapeutics, setting a price target of $4.0. The consensus among analysts is a strong buy, with a mean target price of $5.38 based on eight analyst opinions.
About Context Therapeutics
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for solid tumors. Headquartered in Philadelphia, Pennsylvania, the company is led by CEO Martin A. Lehr and employs approximately 15 people. Its key product candidate, CTIM-76, is a bispecific antibody targeting Claudin 6 for cancer therapy. Context Therapeutics collaborates with Integral Molecular, Inc. in developing this therapy.
Bottom Line
Stacey Jennifer Evans' purchase adds to the insider activity at Context Therapeutics, reflecting a vote of confidence in the company. Investors closely follow such insider transactions as potential indicators of the company's prospects. However, these transactions do not provide a current snapshot, as they are reported after the fact.
Get Context Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $CNTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.